TSLPR抗体;TSLPR Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using TSLPR mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using TSLPR mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using TSLPR mouse mAb with DAB staining.    

  
  

TSLPR (thymic stromal lymphopoietin receptor) is a cytokine receptor subunit that pairs with IL-7Rα to form a functional receptor complex for thymic stromal lymphopoietin (TSLP), a key cytokine involved in type 2 immune responses. Discovered in the early 2000s, TSLPR belongs to the hematopoietin receptor family and is primarily expressed on dendritic cells, mast cells, and certain T-cell subsets. TSLP signaling through TSLPR/IL-7Rα activates downstream pathways like JAK-STAT, MAPK, and PI3K, driving allergic inflammation and promoting Th2 cytokine production.

Research has highlighted TSLPR's critical role in asthma, atopic dermatitis, and eosinophilic disorders. Its involvement in bridging innate and adaptive immunity made it a therapeutic target. TSLPR-blocking antibodies emerged as potential biologics to disrupt pathogenic TSLP signaling. Preclinical studies demonstrated efficacy in reducing airway inflammation and IgE production. In clinical trials, anti-TSLPR agents (e.g., tezepelumab) showed promise in moderate-to-severe asthma by attenuating exacerbations across multiple patient phenotypes, leading to FDA approval for tezepelumab in 2021. Ongoing research explores its utility in other TSLP-mediated conditions, including chronic urticaria and food allergies. However, long-term safety and broader immunomodulatory effects require further investigation.